Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Universal Donor Cancer Immunotherapy To Be Developed By Regen Biopharma

XTALKS VITALS NEWS

Blood

As part of a provisional patent application, the company plans to create cord blood-derived killer cells, which will be paired with gene silencing techniques to target and destroy cancer cells.

Share this!

May 24, 2016 | by Sarah Massey, M.Sc.

Early-stage biotech company, Regen BioPharma, has started preclinical development on the first cancer immunotherapy using cells extracted from cord blood. The San Diego-based company will focus on developing a therapy targeting the NR2F6 immunological checkpoint.

As part of a provisional patent application, the company plans to create cord blood-derived killer cells, which will be paired with gene silencing techniques to target and destroy cancer cells. The potential benefit of this product – known as ucVax – is that the platform will act as a universal donor for cellular immunotherapy. This means that the cells could be frozen and delivered to site of use, without requiring the hospital or treatment center to perform any complicated cellular engineering.

“Developing a universal donor immunotherapy will substantially reduce costs of clinical implementation and allow for wide access to treatment including at institutions that do not possess cellular processing abilities,” said David Koos, chairman and CEO of Regen BioPharma. “To our knowledge, universal donor cellular immunotherapies have not been developed to date. We believe ucVax will possess both therapeutic and commercial advantages as compared to other immunotherapies.”



Current cancer immunotherapy processes are labor-intensive, involving extraction, manipulation and subsequent re-infusion of a patient’s blood cells. While it has proved to be a promising new tool in cancer treatment, it’s also a costly form of personalized medicine.

Regen BioPharma’s ucVax product is, admittedly, in the very early stages of development, and much more research and development must be performed before the product could ever be used in a clinical setting. What’s more, the company says they’re only planning to develop the product from preclinical to midstage testing, which suggests they’ll be looking for future partners capable of getting the technology to market.

“By using cord blood cells as the starting population for generation of ucVax, we overcome the problem of immune rejection by the patient receiving the therapy, thus potentially allowing the therapy to be used by everyone in need,” said Harry Lander, president and CSO of Regen BioPharma. The biotech’s overall focus is in the regenerative medicine space, with other immunotherapy and stem cell treatments currently in development.


Keywords: Immunotherapy, Cancer, Biotech


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Researchers Identify Role of ApoE4 Gene as Possible Drug Target in Alzheimer’s Disease

September 21, 2017 - A team of neurology researchers at Washington University School of Medicine in St. Louis have found that in the presence of the ApoE4 protein, another protein known as tau forms tangles in the brain which contributes to neuronal damage characteristic of Alzheimer’s disease.

Featured In: Life Science News


New Guidelines Address CAR-T Immunotherapy Toxicities to Prevent Patient Deaths

September 20, 2017 - Clinicians at The University of Texas MD Anderson Cancer Center have published new guidelines in the journal, Nature Reviews Clinical Oncology, which could help in the management of these toxicities.

Featured In: Biotech News, Drug Safety News


Microneedle Skin Patch Could Treat Common Metabolic Disorders

September 19, 2017 - Researchers at Columbia University Medical Center (CUMC) and the University of North Carolina have developed a microneedle skin patch impregnated with a drug capable of converting white fat into calorie-burning brown fat.

Featured In: Medical Device News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Five Reasons Why Toronto is Emerging as a Major Life Sciences Hub

REGISTER FOR THESE WEBINARS

Development and Manufacture of Highly Potent API Drug Products Throughout the Clinical Phases


Innovation through Integration – Providing Next Generation Biomedical Devices and Interconnects


Clinical Payments Case Studies: Improving Efficiency, Cash Management, and Compliance


Why Phase 3 Trials Fail: Oncology Case Studies and Lessons Learned


Copyright © 2016-2017 Honeycomb Worldwide Inc.